Torrent Pharma’s Bileshwarpura Oncology Facility Clears USFDA Inspection with Zero Observations

Torrent Pharmaceuticals has successfully completed a USFDA inspection at its Bileshwarpura oncology manufacturing facility, with the audit concluding on April 10, 2026, after a five-day review. The inspection resulted in a clean report with zero observations, meaning no Form 483 citations were issued. This positive outcome reflects the company’s adherence to stringent quality standards and reinforces the facility's compliance with global regulatory requirements. The clean EIR underscores Torrent’s strong operational and quality control systems, ensuring uninterrupted supply of its oncology portfolio to key regulated markets like the United States. The successful audit strengthens investor confidence and highlights Torrent’s commitment to excellence in pharmaceutical manufacturing.